BH-30643
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BH-30643, covering 2026-04-24 to 2026-04-24. Get the full timeline:
Most recent: Clinical Trial Update: A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations [Phase 1, Phase 2]